Apoptosis in cultured hNT neurons.
Programmed cell death (apoptosis) is an important mechanism shaping the size of different cell populations within the developing nervous system. In our study we used the NT2/D1 clone originally established from the Ntera 2 cell line to investigate the baseline levels of apoptosis in cultured postmitotic hNT (NT2-N) neurons previously treated for 3, 4 or 5 weeks with retinoic acid (RA) and compared it with apoptosis in NT2 precursors unexposed to RA. First, we examined whether different lengths of exposure to RA might affect baseline apoptotic rate in differentiating hNT neurons. Second, we investigated whether cultured hNT neurons, previously shown to possess dopaminergic characteristics, would be preferentially affected by apoptosis. Using the terminal deoxynucleotidyl transferase (tdt)-labeling technique we found that the postmitotic hNT neuronal cells exposed to RA demonstrated significantly higher numbers of apoptotic cells (12.5-15.8%) in comparison to rapidly dividing NT2 precursor cell line (3.6-4.4%) at both studied (1 and 5 days in vitro, DIV) time points. Similar apoptotic nuclear morphology, including a variable extent of nuclear fragmentation was observed in all examined hNT cultures. On the other hand, the incidence of apoptotic nuclei was rare in cultures of NT2 precursors not subjected to RA treatment. Combined immunocytochemistry for tyrosine hydroxylase (TH) and Hoechst staining revealed dopaminergic hNT neurons destined to die. Our double-labeling studies have demonstrated that only a subset of TH-positive hNT cells had condensed chromatin after 1 (approx. 15%) and 5 (approx. 20%) DIV. NT2 precursors were not TH-positive. Collectively, our results demonstrated that exposure to differentiating agent RA triggers an apoptotic commitment in a subset of postmitotic hNT neurons. These results suggest that this cell line may serve as a model of neuronal development to test various pathogenic factors implicated in the etiology of Parkinson's disease (PD), as well as to screen numerous pharmacological treatments that may slow or prevent dopaminergic deterioration.
Zigova
T
T
Department of Neurosurgery, College of Medicine, University of South Florida, Tampa 33612, FL, USA. tzigova@com1.med.usf.edu
Willing
A E
AE
Saporta
S
S
Daadi
M M
MM
McGrogan
M P
MP
Randall
T S
TS
Freeman
T B
TB
Sanchez-Ramos
J
J
Sanberg
P R
PR
D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D004253:DNA Nucleotidylexotransferase / Q000032:analysis; D004298:Dopamine / Q000502:physiology; D006801:Humans; D009373:Neoplasms, Germ Cell and Embryonal; D009474:Neurons / Q000166:cytology* / Q000201:enzymology; D013234:Stem Cells / Q000166:cytology / Q000201:enzymology; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis
D000970:Antineoplastic Agents; D014212:Tretinoin; D014446:Tyrosine 3-Monooxygenase; D004253:DNA Nucleotidylexotransferase; D004298:Dopamine